CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

Abstract Introduction Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cogni...

詳細記述

書誌詳細

主要な著者:	Nathan Herrmann, Zahinoor Ismail, Rhonda Collins, Philippe Desmarais, Zahra Goodarzi, Alexandre Henri‐Bhargava, Andrea Iaboni, Julia Kirkham, Fadi Massoud, Andrea Moser, James Silvius, Jennifer Watt, Dallas Seitz
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2022-01-01
シリーズ:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
主題:	cholinesterase inhibitor memantine cognitive enhancer dementia deprescribing discontinuation
オンライン･アクセス:	https://doi.org/10.1002/trc2.12099
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!